Cue Biopharma, Inc. CUE
Biotechnology: Pharmaceutical Preparations · IPO 2018 · data as of November 13, 2026
Cue Biopharma, Inc. (CUE) is a healthcare company listed in the US with a market value of about $117M. In the twelve months to June 30, 2026 it had revenue of $38M and net income of -$164M, a net margin of -435.8%.
Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 54% a year, a 5-year average ROIC of -83%.
About Cue Biopharma
Cue Biopharma is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2018. Revenue went from $1M in 2018 to $27M in 2025, growth of about 57.5% a year. It was profitable in 0 of the last 9 years in our data. Its share count rose by 166% over three years (dilution for shareholders). It spends 137% of revenue on research and development.
Score: 1.4 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 9 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $38M | $27M | $9M | $5M | $1M | $15M | $3M | $3M | $1M | — |
| Net income | -$164M | -$27M | -$41M | -$51M | -$53M | -$44M | -$45M | -$37M | -$39M | -$23M |
| Free cash flow | -$50M | -$22M | -$36M | -$40M | -$42M | -$40M | -$33M | -$31M | -$28M | -$13M |
| EPS (diluted) | $-25.26 | $-0.28 | $-0.72 | $-1.11 | $-1.49 | $-1.41 | $-1.56 | $-1.66 | $-1.94 | $-2.16 |
| Net margin | -435.8% | -96.9% | -438.0% | -924.1% | -4257.8% | -295.6% | -1419.8% | -1061.2% | -3411.5% | — |
| ROIC | — | -68.5% | -148.5% | -91.0% | -62.6% | -45.7% | -41.3% | -48.1% | -90.0% | -29.8% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Cue Biopharma pay a dividend?
Not currently.
Is Cue Biopharma a good stock to buy?
We do not give buy or sell advice. Cue Biopharma scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.